Gossamer Bio Inc (GOSS) has shared an update.
Gossamer Bio, Inc. has entered into a strategic collaboration with Chiesi Farmaceutici to develop and commercialize seralutinib for conditions like pulmonary arterial hypertension. This global agreement grants Chiesi exclusive licenses to Gossamer’s intellectual property, with shared responsibilities and profits for US sales and Chiesi leading efforts outside the US. Gossamer will receive an upfront payment of $160 million, with potential for additional milestone payments totaling $326 million, and royalties on overseas sales. Additionally, Chiesi has an option to acquire a stake in Gossamer. This alliance signifies a significant step in bringing new treatments to market for serious respiratory conditions.
Find detailed analytics on GOSS stock on TipRanks’ Stock Analysis page.
